125P Publicly funded testing for germline BRCA1/2 pathogenic variants in ovarian cancer in Australia: A population-based study

Pathogenic variants in BRCA1/2 are an established genetic risk factor for ovarian cancer, with implications for inherited cancer predisposition and treatment selection. In Australia, routine germline BRCA1/2 testing (‘mainstreaming’) was introduced in 2017 for all people diagnosed with non-mucinous high-grade epithelial ovarian, tubal or primary peritoneal cancer. Although this testing is publicly funded on the Medicare Benefits Schedule (MBS), the extent of uptake and equity of access in the population is unclear.